- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04838210
Elevating Voices, Addressing Depression, Toxic Stress and Equity in Group Prenatal Care (EleVATE GC)
November 28, 2023 updated by: Washington University School of Medicine
This study will provide high-quality, representative data on the capacity of Elevating Voices, Addressing Depression, Toxic Stress and Equity in Group Prenatal Care (EleVATE GC) to reduce perinatal depression, preterm birth, and low birthweight in African-American women.
If findings from this study indicate that EleVATE GC is feasible and effective, this model could be implemented nationwide to help achieve mental and obstetric health parity for low-income women of color in the United States.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
390
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- University of Missouri-Kansas City/Truman Health Centers-Kansas City
-
Saint Louis, Missouri, United States, 63104
- Affinia Healthcare
-
Saint Louis, Missouri, United States, 63111
- Family Care Health Centers
-
Saint Louis, Missouri, United States, 63112
- CareSTL Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
11 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- English or Spanish speaking
- ≤18 weeks' gestation
- Established prenatal care at EleVATE site
- High-risk for postpartum depression by ≥1 risk factor (personal/family history, baseline EPDS≥10, low-income, 13-19 years old, single, history of physical/sexual abuse, unplanned/undesired pregnancy, history of pregnancy loss)
- Ability to attend group prenatal visits at specified days/times
- Willingness to be randomized
- Ability to give informed consent
- Any patient that has received prenatal care in a group setting previously
Exclusion Criteria:
- Multiple gestation
- Major fetal anomaly
- Serious medical co-morbidity/psychiatric illness necessitating more care than can be safely provided in group setting
- Serious medical co-morbidity necessitating more care than can be safely provided in group setting
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group Prenatal Care
Group prenatal care model
|
10-session (2 hours per session) group prenatal care model following the prenatal visit schedule recommended by ACOG.
In addition to pregnancy and infant-care related content, the EleVATE GC curriculum includes behavioral health strategies that can be used to manage depression and labor pain and navigate the daily frustrations and stress of life.
Groups are facilitated by an obstetric clinician.
|
Active Comparator: Individual Prenatal Care
Individual prenatal care
|
The dominant model of prenatal care in the United States, consisting of one-on-one encounters between a patient and obstetric clinician.
Patients are seen for 10-15 mins every 4 weeks until 28 weeks gestation, every 2 weeks until 37 weeks or more by provider discretion), and weekly until delivery.
Visits focus on routine screening tests and prenatal care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perinatal Depression
Time Frame: Baseline visit
|
Major Depression (Edinburgh Postnatal Depression Scale Score, range: 0-30, higher scores are a worse outcome)
|
Baseline visit
|
Perinatal Depression
Time Frame: 28-40 week visit
|
Major Depression (Edinburgh Postnatal Depression Scale Score, range: 0-30, higher scores are a worse outcome)
|
28-40 week visit
|
Perinatal Depression
Time Frame: 4-12 weeks Postpartum
|
Major Depression (Edinburgh Postnatal Depression Scale Score, range: 0-30, higher scores are a worse outcome)
|
4-12 weeks Postpartum
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Preterm Birth
Time Frame: Delivery
|
Delivery at <37 weeks gestation
|
Delivery
|
Small for Gestational Age
Time Frame: Delivery
|
Birthweight <10th percentile on the Alexander growth curve
|
Delivery
|
Perceived Stress
Time Frame: Baseline visit
|
Perceived Stress Scale Total Scores, range: 0-40, higher scores are a worse outcome
|
Baseline visit
|
Perceived Stress
Time Frame: 28-40 week
|
Perceived Stress Scale Total Scores, range: 0-40, higher scores are a worse outcome
|
28-40 week
|
Perceived Stress
Time Frame: 4-12 weeks Postpartum
|
Perceived Stress Scale Total Scores, range: 0-40, higher scores are a worse outcome
|
4-12 weeks Postpartum
|
Anxiety
Time Frame: Baseline visit
|
PROMIS Short Form Anxiety 8a T-Score, range: 37.1-83.1,
higher scores are a worse outcome
|
Baseline visit
|
Anxiety
Time Frame: 28-40 week visit
|
PROMIS Short Form Anxiety 8a T-Score, range: 37.1-83.1,
higher scores are a worse outcome
|
28-40 week visit
|
Anxiety
Time Frame: 4-12 weeks Postpartum
|
PROMIS Short Form Anxiety 8a T-Score, range: 37.1-83.1,
higher scores are a worse outcome
|
4-12 weeks Postpartum
|
Post-Traumatic Stress Disorder (PTSD)
Time Frame: Baseline Visit
|
PTSD Checklist for DSM-V Total Symptom Severity Score, range 0-80, higher scores are a worse outcome
|
Baseline Visit
|
Social Support
Time Frame: Baseline visit
|
PROMIS Bank 2.0 Social Support (emotional support, instrumental support, informational support, and social isolation domains) T-Scores, range 23.7-76.9,
higher scores are better outcomes for emotional support, instrumental support and informational support, higher scores are worse outcomes for social isolation
|
Baseline visit
|
Social Support
Time Frame: 28-40 week visit
|
PROMIS Bank 2.0 Social Support (emotional support, instrumental support, informational support, and social isolation domains) T-Scores, range 23.7-76.9,
higher scores are better outcomes for emotional support, instrumental support and informational support, higher scores are worse outcomes for social isolation
|
28-40 week visit
|
Social Support
Time Frame: 4-12 weeks Postpartum
|
PROMIS Bank 2.0 Social Support (emotional support, instrumental support, informational support, and social isolation domains) T-Scores, range 23.7-76.9,
higher scores are better outcomes for emotional support, instrumental support and informational support, higher scores are worse outcomes for social isolation
|
4-12 weeks Postpartum
|
Race-Related Stress
Time Frame: Baseline visit
|
Index of Race Related Stress-Brief Version Total Score, range 0-22, higher scores are worse outcomes
|
Baseline visit
|
Maternal Attachment (Antenatal)
Time Frame: Baseline visit
|
Maternal Antenatal Attachment Scale Total Score, range 19-95, higher scores are better outcomes
|
Baseline visit
|
Maternal Attachment (Antenatal)
Time Frame: 28-40 week visit
|
Maternal Antenatal Attachment Scale Total Score, range 19-95, higher scores are better outcomes
|
28-40 week visit
|
Maternal Attachment (Postnatal)
Time Frame: 4-12 Weeks Postpartum
|
Maternal Postnatal Attachment Scale Total Score, range 19-95, higher scores are better outcomes
|
4-12 Weeks Postpartum
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 21, 2021
Primary Completion (Estimated)
June 30, 2025
Study Completion (Estimated)
June 30, 2025
Study Registration Dates
First Submitted
March 18, 2021
First Submitted That Met QC Criteria
April 6, 2021
First Posted (Actual)
April 9, 2021
Study Record Updates
Last Update Posted (Actual)
December 5, 2023
Last Update Submitted That Met QC Criteria
November 28, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202103142
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy Related
-
Helen Keller InternationalEleanor Crook FoundationNot yet recruitingPregnancy Related | Supplementation | Postnatal Related
-
4YouandMeCambridge Cognition Ltd; Sema4; Evidation Health; Vector Institute of Artificial... and other collaboratorsCompletedPregnancy Related | Wearables | Pregnancy EarlyUnited States
-
The University of Texas Health Science Center,...CompletedPregnancy Related | Pregnancy, High RiskUnited States
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Shaare Zedek Medical CenterUnknownPregnancy Related | Pregnancy, High Risk | Anesthesia
-
University of CopenhagenStanford UniversityRecruitingPregnancy RelatedDenmark
-
European Vaccine InitiativeKintampo Health Research Centre, Ghana; Groupe de Recherche Action en Sante; Fondation... and other collaboratorsRecruitingPregnancy RelatedBenin, Burkina Faso, Ghana, Malawi
-
Kahramanmaras Sutcu Imam UniversityNot yet recruitingPregnancy RelatedTurkey
-
Fondation Hôpital Saint-JosephRecruiting
-
German Institute of Human NutritionRecruiting
Clinical Trials on EleVATE Group Care
-
ASTORA Women's HealthCompletedVaginal ProlapseUnited States
-
University of GeorgiaDepartment of Health and Human ServicesWithdrawnFamily RelationsUnited States
-
Emanuel TrabucoAmerican Medical SystemsTerminatedPelvic Organ ProlapseUnited States, Germany
-
Auburn UniversityDepartment of Health and Human Services; Mathematica Policy Research, Inc.CompletedHealthy Marriage | Healthy RelationshipUnited States
-
Hospices Civils de LyonCompleted
-
Magenta Medical Ltd.RecruitingHigh-risk Percutaneous Coronary InterventionUnited States
-
Magenta Medical Ltd.Active, not recruitingHigh-Risk Percutaneous Coronary InterventionGeorgia
-
ASTORA Women's HealthTerminatedPelvic Organ Prolapse | Female Stress IncontinenceUnited States, Spain, Slovenia, France, United Kingdom, Canada, Germany, South Africa
-
Centre Hospitalier Universitaire de NīmesTerminated
-
Francisco CarmonaAmerican Medical SystemsActive, not recruitingCystocele | Uterine Prolapse | Vaginal Vault Prolapse | Rectocele | EnteroceleSpain